Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Results 1 - 8 of about 8 for David E. Graves
Company Exchange Symbol Last price Quote change Market cap
Achillion Pharmaceuticals, Inc. NASDAQ ACHN 6.07 +0.11 (1.85%) 842.97M
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule ...
Executive:
David Apelian MD, Ph.D.
MTS Systems Corporation NASDAQ MTSC 53.90 +2.85 (5.58%) 784.60M
MTS Systems Corporation (MTS) is a global supplier of test systems and position sensors. The Company's operations are organized and managed in two business ...
Executive:
David D. Johnson
Independent Bank Corporation(MI) NASDAQ IBCP 14.48 +0.07 (0.49%) 321.31M
Independent Bank Corporation is a bank holding company. The Company owns all of the outstanding stock of Independent Bank (the Bank).
Executive:
David C. Reglin
DTS Inc. NASDAQ DTSI 21.78 +0.28 (1.30%) 373.21M
DTS, Inc. is an audio technology solutions provider for high-definition entertainment experiences. The Company's audio solutions are designed to enable ...
Executive:
David C. Habiger
Eagle Pharmaceuticals Inc NASDAQ EGRX 54.24 +1.88 (3.60%) 829.51M
Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable ...
Executive:
David E. Riggs
Oaktree Capital Group LLC NYSE OAK 48.19 +1.66 (3.57%) 7.86B
Oaktree Capital Group, LLC (Oaktree) is a global investment manager specializing in alternative investments. The Company manages investments in a range of ...
Executive:
David M. Kirchheimer
Oaktree Capital Group LLC OTCMKTS OKCMZ
Oaktree Capital Group, LLC (Oaktree) is a global investment management firm focused on alternative markets. Oaktree manages funds in investment strategies ...
Executive:
David M. Kirchheimer
Pulmatrix Inc NASDAQ PULM 2.50 -0.10 (-3.85%) 31.98M
Pulmatrix, Inc., formerly Ruthigen, Inc., is a clinical stage biotechnology company. The Company is engaged in developing inhaled therapies to address ...
Executive:
David L Hava Ph.D.